 |
市场调查报告书
商品编码
1616276
阿霉素市场机会、成长动力、产业趋势分析和 2024 年至 2032 年预测Doxorubicin Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032 |
||||||
2023 年，全球阿霉素市场价值为13 亿美元，预计2024 年至2032 年复合年增长率为6.3%。于治疗各种癌症。它破坏癌细胞的 DNA，阻止其生长和分裂，最终导致细胞死亡。全球癌症发病率的飙升极大地推动了市场的扩张。例如，世界卫生组织(WHO) 报告称，2022 年预计将有2,000 万新癌症病例和970 万名癌症相关死亡病例。上升的癌症负担需要晚期和癌症治疗。
此外，化疗的创新、对个人化医疗的重视以及政府对癌症研究投资的增加进一步促进了阿霉素市场的收入成长。整个阿霉素产业根据应用、药物配方、配销通路和地区进行分类。以剂型划分，阿霉素市场包括冷冻干燥粉针剂和阿霉素注射剂。预测显示，到 2032 年，阿霉素注射液市场将达到 13 亿美元。 阿霉素可有效治疗多种癌症，包括但不限于乳癌、淋巴瘤、白血病和肉瘤。
其广谱功效使其成为关键的治疗选择。可注射的变体增强了这种多功能性，确保快速作用和全身治疗，使药物能够迅速作用于全身的癌细胞。阿霉素的应用范围涵盖肝癌、乳癌、肺癌和肾癌等。 2023 年，光是乳癌领域就创造了 3.018 亿美元的收入。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 13亿美元 |
| 预测值 | 22亿美元 |
| 复合年增长率 | 6.3% |
由于其广泛的癌细胞靶向性，阿霉素的适应性使其能够应用于从早期检测到转移阶段的所有乳癌阶段。这种灵活性不仅巩固了其在不同临床场景中的重要性，而且解释了乳癌细分市场的主导市场份额。在美国，阿霉素市场预计到 2032 年将达到 7.717 亿美元。美国疾病管制与预防中心 (CDC) 的数据显示，2020 年，新诊断出 1,603,844 例癌症，其中 602,347 例死亡。此外，美国拥有先进的医疗保健框架，拥有先进的医院和专门的癌症中心，确保阿霉素治疗的最佳管理。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 癌症盛行率增加
- 化疗治疗的进展
- 日益关注个人化医疗
- 政府对癌症研究的资助增加
- 产业陷阱与挑战
- 替代疗法的可用性
- 与药物相关的副作用
- 成长动力
- 成长潜力分析
- 技术景观
- 监管环境
- 未来市场趋势
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按药物配方，2021 - 2032 年
- 主要趋势
- 冻干粉
- 阿霉素注射液
第 6 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 乳癌
- 肝癌
- 肾癌
- 肉瘤
- 卵巢癌
- 肺癌
- 白血病
- 多发骨髓瘤
- 其他类型的癌症
第 7 章：市场估计与预测：按配销通路，2021 - 2032 年
- 主要趋势
- 医院药房
- 零售药房
- 网路药房
第 8 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 9 章：公司简介
- Accord Healthcare
- Baxter International Inc.
- Cipla Ltd.
- Dr. Reddy's Laboratories Limited
- Fresenius SE & Co. KGaA
- Johnson and Johnson
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Meiji Holdings Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Limited
The Global Doxorubicin Market was valued at USD 1.3 billion in 2023 and is projected to depict a 6.3% CAGR from 2024 to 2032. Doxorubicin, derived from the bacterium Streptomyces Peucetius, is an anthracycline-based chemotherapy drug predominantly used to treat various cancers. It disrupts the DNA of cancer cells, halting their growth and division, and ultimately leading to cell death. The surging global cancer incidence significantly propels the market's expansion. For example, the World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. Such statistics highlight the escalating demand for potent chemotherapy agents like doxorubicin, as the rising cancer burden calls for advanced and widely adopted treatment modalities.
Moreover, innovations in chemotherapy, an emphasis on personalized medicine, and heightened government investments in cancer research further bolster the doxorubicin market's revenue growth. The overall doxorubicin industry is classified based on application, drug formulation, distribution channel, and region. Segmented by drug formulations, the doxorubicin market comprises lyophilized powder and doxorubicin injection. Projections suggest the doxorubicin injection segment will hit USD 1.3 billion by 2032. Doxorubicin effectively targets a myriad of cancers, including but not limited to breast cancer, lymphoma, leukemia, and sarcoma.
Its broad-spectrum efficacy positions it as a pivotal treatment choice. The injectable variant amplifies this versatility, ensuring swift action and systemic treatment, allowing the drug to promptly engage cancer cells throughout the body. Applications of doxorubicin span liver, breast, lung, and kidney cancers, among others. In 2023, the breast cancer segment alone generated USD 301.8 million.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $1.3 Billion |
| Forecast Value | $2.2 Billion |
| CAGR | 6.3% |
Doxorubicin's adaptability allows its application across all breast cancer stages, from early detection to metastatic phases, thanks to its broad cancer cell targeting. This flexibility not only solidifies its significance in varied clinical scenarios but also explains the breast cancer segment's dominant market share. In the U.S., the doxorubicin market is on track to reach USD 771.7 million by 2032. The rising cancer prevalence in the U.S. significantly fuels the doxorubicin market's growth. Data from the Centers for Disease Control and Prevention (CDC) indicates that in 2020, there were 1,603,844 new cancer diagnoses, with 602,347 resulting in fatalities.Such rising figures underscore the urgent demand for effective therapeutic solutions. Moreover, the U.S. is home to a sophisticated healthcare framework, featuring advanced hospitals and specialized cancer centers, ensuring optimal management of doxorubicin therapies.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cancer
- 3.2.1.2 Advancements in chemotherapy treatments
- 3.2.1.3 Growing focus on personalized medicine
- 3.2.1.4 Growth in government funding for cancer research
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Availability of alternative therapies
- 3.2.2.2 Side effects associated with the medication
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technology landscape
- 3.5 Regulatory landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Formulation, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Lyophilized powder
- 5.3 Doxorubicin injection
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Breast cancer
- 6.3 Liver cancer
- 6.4 Kidney cancer
- 6.5 Sarcoma
- 6.6 Ovarian cancer
- 6.7 Lung cancer
- 6.8 Leukemia
- 6.9 Multiple myeloma
- 6.10 Other types of cancer
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Accord Healthcare
- 9.2 Baxter International Inc.
- 9.3 Cipla Ltd.
- 9.4 Dr. Reddy's Laboratories Limited
- 9.5 Fresenius SE & Co. KGaA
- 9.6 Johnson and Johnson
- 9.7 Hikma Pharmaceuticals PLC
- 9.8 Lupin Limited
- 9.9 Meiji Holdings Co. Ltd.
- 9.10 Novartis AG
- 9.11 Pfizer Inc.
- 9.12 Sun Pharmaceutical Industries Ltd.
- 9.13 Sanofi
- 9.14 Teva Pharmaceutical Industries Ltd.
- 9.15 Viatris Inc.
- 9.16 Zydus Lifesciences Limited
